|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||6.76 - 7.85|
|52-week range||2.85 - 10.23|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.00|
MIAMI, Fla., July 29, 2021--Flora Growth Corp. (NASDAQ: FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has entered into a non-binding Letter of Intent ("LOI") with Evergreen Pharmacare Pty Ltd. ("Evergreen"), a licensed Australian importer and distributor of medical cannabis products, to supply its premium dried flower and derivative products. The Company expects to ship its medical-grade
Flora Growth (NASDAQ: FLGC) surged as high as $7.95 in afternoon trading Wednesday, a rise of more than 50% to the highest level the stock has touched since its initial public offering in May. Colombia-based Flora, which just announced plans to move its corporate headquarters to Miami from Canada, cultivates cannabis and processes it into medicinal-grade cannabis oil and other products, which it supplies to pharmacies, cosmetics companies, and medical clinics. The cream, already sold in Canada, will now also be sold through Flora's distribution channels in Latin America.
MIAMI, July 27, 2021--Flora Growth Corp. (NASDAQ: FLGC) ("Flora", "Flora Growth", or the "Company"), an all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce it has signed a non-binding Letter of Intent ("LOI") to form a joint venture ("the JV") with Canadian based Avaria Inc ("Avaria"), the manufacturer and owner of KaLaya – an award-winning pain cream distributed nation-wide across Canada.